Surgery Partners (SGRY) Aandeel Koers
Surgery Partners Koers
De omzet is de afgelopen 14 jaar met 23,2% per jaar gegroeid tot 3,31 Miljard USD. De winst per aandeel is de afgelopen 4 jaar met 43,4% per jaar gedaald. De nettowinstmarge van Surgery Partners ligt op -2,4% en is ten opzichte van -3,2% enkele jaren eerder grotendeels stabiel. Analisten hanteren een mediaan koersdoel van 18,50 USD — dat impliceert 20,3% onder de huidige koers. Van de 18 analisten geven 14 het aandeel een koopadvies — per saldo een Kopen-consensus.
Surgery Partners aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Surgery Partners bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Surgery Partners
Surgery Partners Inc is primarily active in the healthcare industry. With a focus on providing surgical services, the company operates a network of outpatient surgical facilities, physician practices, and anesthesia services. By offering a comprehensive range of surgical solutions, Surgery Partners Inc aims to improve patient outcomes and enhance healthcare delivery. With its expertise in specialties such as orthopedics, gastroenterology, and ophthalmology, the company plays a crucial role in meeting the diverse healthcare needs of patients across different regions. Overall, Surgery Partners Inc's activities support the advancement and accessibility of quality healthcare services.
The business model of Surgery Partners Inc centers around providing a comprehensive range of surgical services through its network of ambulatory surgery centers, surgical hospitals, and contract services. With a focus on delivering high-quality, cost-effective care, Surgery Partners Inc aims to meet the needs of patients, physicians, and healthcare facilities. By offering a diverse range of surgical specialties, including orthopedics, gastroenterology, and ophthalmology, Surgery Partners Inc strives to improve patient outcomes and satisfaction. Through its strategic partnerships and operational expertise, the company continues to expand its footprint and strengthen its position within the healthcare industry.
The main competitors of Surgery Partners Inc in the market include Tenet Healthcare Corporation, HCA Healthcare, and UnitedHealth Group.
Surgery Partners Inc is a leading healthcare services company with an extensive history in the industry. Established in 2004, Surgery Partners has since grown to become a prominent player in providing surgical services across the United States. With a focus on delivering high-quality care in a cost-effective manner, the company operates a network of surgical facilities and ancillary services centers. Through strategic partnerships, Surgery Partners offers a range of surgical procedures in various specialties, ensuring access to a wide range of patients in need. With their commitment to exceptional patient care, Surgery Partners Inc has established itself as a trusted name in the healthcare sector.
Surgery Partners Inc has achieved several significant milestones in its history. One notable accomplishment includes the strategic acquisition of National Surgical Healthcare in 2017, which expanded the company's reach and capabilities in the outpatient surgical market. Additionally, Surgery Partners Inc achieved recognition as a leader in ambulatory surgery, providing high-quality healthcare services across multiple states. The company has also demonstrated consistent growth and financial performance, further establishing its position in the healthcare industry. Surgery Partners Inc continues to prioritize patient care and innovation, driving its success and reinforcing its reputation as an esteemed company in the stock market.
Surgery Partners Inc is primarily present in the United States.
Surgery Partners Inc values the highest standards of patient care, innovation, and excellence in healthcare services. With a patient-centric approach, the company strives to provide the most advanced surgical solutions and personalized care. The corporate philosophy revolves around compassionate healthcare delivery, continuous improvement, and ethical practices. Surgery Partners Inc is committed to fostering strong relationships with physicians, patients, and partners, while maintaining a focus on operational efficiency and financial strength. The company's dedication to quality outcomes, cutting-edge technology, and commitment to patient satisfaction embodies its core values and corporate philosophy.
Analisten hanteren momenteel een gemiddeld koersdoel van 18,75 USD voor het aandeel Surgery Partners (mediaan: 18,50 USD), oftewel -19,2 % ten opzichte van de laatste koers. De consensus is gebaseerd op 18 analistenratings.
18 analisten beoordelen het aandeel Surgery Partners momenteel: 14 adviseren kopen, 4 houden en 0 verkopen. Voor 2026 verwachten analisten dat Surgery Partners een omzet van 3,35 Miljard USD en winst per aandeel van 0,40 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Surgery Partners op 20,79 EUR (23,21 USD).
Het aandeel Surgery Partners (SGRY) is genoteerd aan 4 beurzen, waaronder: NASDAQ (SGRY), Frankfurt (1SP.F), München (1SP.MU), Düsseldorf (1SP.DU).
Surgery Partners Inc. is a leading healthcare company that focuses on outpatient surgical centers and services for the healthcare industry. The company offers a variety of surgical and diagnostic services delivered on an outpatient basis. Surgery Partners Inc. operates over 180 facilities in 31 states in the USA and provides a wide range of surgical services. The business model of Surgery Partners Inc. is based on the goal of providing its patients with top-quality surgical services and continuous medical care at the highest level. The company has an extensive network of outpatient surgical centers and offers its patients a wide range of surgical and diagnostic services, including general surgery, orthopedics, ophthalmology, neurology, gastroenterology, gynecology, and many others. Surgery Partners Inc. also offers specialized procedures and services such as endoscopic examinations, imaging services, pain therapy, and rehabilitation. The company also operates an extensive diagnostic platform that includes advanced imaging technology and diagnostic procedures such as endoscopy and biopsy. The company also has a focus on the development and utilization of cutting-edge technology in surgery and diagnostics to ensure that patients receive excellent medical care. Surgery Partners Inc. also maintains extensive partnerships with healthcare providers and hospitals to enable better coordinated care. The company collaborates with numerous facilities to meet the needs of patients and provide them with a seamless healthcare experience. These partnerships allow Surgery Partners Inc. to expand its network of facilities and improve its services. Surgery Partners Inc. is also actively involved in research and development, working to develop new procedures and technologies to improve surgical services. The company has a strong team of researchers and physicians who continuously seek new opportunities to enhance surgery and diagnostics, thereby ensuring better healthcare. Overall, the business model of Surgery Partners Inc. is focused on providing top-quality surgical and diagnostic services on an outpatient basis. The company operates an extensive network of surgical facilities and offers a wide range of surgical and diagnostic services to meet the needs of its patients. Through healthcare partnerships and the use of cutting-edge technologies, Surgery Partners Inc. strives to provide better healthcare for its patients.
De verwachte omzet van Surgery Partners bedraagt 3,35 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Surgery Partners bedraagt 51,10 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Surgery Partners bedraagt momenteel 57,78. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Surgery Partners-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Surgery Partners bedraagt momenteel 0,88. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Surgery Partners-aandeel.
De Eulerpool Kwaliteitsscore voor Surgery Partners is 3/10.
De ISIN van Surgery Partners is US86881A1007. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Surgery Partners is A14YWP. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Surgery Partners is SGRY. Onder dit beurstickersymbool wordt het Surgery Partners-aandeel op de beurs verhandeld.
Surgery Partners aandeel
Surgery Partners Peer Group
Surgery Partners Ticker
Surgery Partners FIGI
Alle fundamentals en diepgaande analyse van Surgery Partners
Onze aandelenanalyse van het Surgery Partners-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Surgery Partners. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: